Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005...


Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005 brain cancer drug. Shares -12.2% AH to $1.30.
Comments (2)
  • shel113
    , contributor
    Comments (17) | Send Message
     
    I sold of my Gern not long after they got out of the Stem Cell business. I mad a few dollars (but got hit when the stock price dived) but the reason for the purchase was buying into a leader in stem cell development. The company seemed to be going downhill and after holing on for some time it was time to hang it up. I am sorry that a company with what appeared to have cutting edge technology (which may yet be developed by Bio Time) has deteriorated to a point where it may cease to exist. I am considering Bio Time as an investment as I still believe that Geron's stem cell technology is very viable and has investment potential.
    3 Dec 2012, 05:08 PM Reply Like
  • Wilbe
    , contributor
    Comments (2) | Send Message
     
    This company must be poorly led because this is the second or third thing they have terminated. I have lost quite a bit on this poorly run company.
    3 Dec 2012, 08:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs